Spirair Announces Publication of Multicenter Study Demonstrating Significant Six-Month Improvements with SeptAlignMOUNTAIN VIEW, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Spirair, Inc., a medical technology company advancing next-generation solutions for ear, nose, and throat care, today announced publication of six-month results from the Vayu Study of SeptAlign®, the company’s FDA-cleared bioresorbable implant for minimally invasive correction of cartilaginous nasal septal deviation. The manuscript, “Safety and Effectiveness of a Bioabsorbable Septal Implant for Cartilaginous Nasal Septal Deviation,” appears in Laryngoscope Investigative Otolaryngology.
First Clinical Study of SeptAlign™ Implant Demonstrates Safety and Efficacy in Treating Nasal Septal Deviation While Preserving Cartilage
Spirair, Inc., an early-stage company developing minimally invasive solutions to help ENTs improve patient care, today announced the publication of the first clinical study evaluating its SeptAlign™ implant. The positive 12-month outcomes demonstrate the safety and efficacy of this novel bioabsorbable device, which offers a cartilage-sparing approach to traditional septoplasty for the treatment of nasal septal deviation (NSD).
